Abstract: Provided herein are methods of treating cancer in a subject, wherein the cancer is extrachromosomal DNA-positive (ecDNA-positive) or therapeutically resistant, the method comprising administering to the subject a therapeutically effective amount of a replication stress (RS) pathway agent alone or in combination with a targeted therapeutic.
Type:
Grant
Filed:
January 4, 2022
Date of Patent:
January 10, 2023
Assignee:
BOUNDLESS BIO, INC.
Inventors:
Christian Hassig, Ryan Hansen, Snezana Milutinovic, Jason Christiansen, Zachary Hornby, Sudhir Chowdhry, Anthony Celeste, Kristen Turner, Deepti Wilkinson
Abstract: Provided herein are methods of treating and/or managing cancers, which comprise administering to a patient Compound A, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in combination with daratumumab. Additionally, provided herein are methods of treating and/or managing cancers, which comprise administering to a patient Compound A, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in combination with daratumumab and dexamethasone.
Type:
Grant
Filed:
September 30, 2019
Date of Patent:
December 20, 2022
Assignee:
CELGENE CORPORATION
Inventors:
Michael D. Amatangelo, Chad Bjorklund, Anjan Thakurta, Xiankang Hong, Mariana Cota
Abstract: Provided here are new ophthalmological methods for the treatment or prophylaxis of ocular bacterial infections and related conditions comprising delivering an effective amount of an ophthalmologically suitable composition comprising an effective amount of a moxifloxacin compound and an effective amount of a triamcinolone compound. In aspects, methods comprise delivery of the composition by injection. In aspects, the delivered compositions are stable suspensions, which maintain physical stability and chemical stability for extended periods of time (e.g., exhibiting no sustained flocculation, coagulation, or clumping after several months of storage under typical storage conditions). In aspects, compositions are suspensions that include a suspension component comprising one or more suspension agents. In aspects, the suspension component includes an ionic suspension and may also or alternatively comprises a non-ionic surfactant, non-ionic suspension agent, or both, or, an agent that provides both functions.
Type:
Grant
Filed:
August 26, 2021
Date of Patent:
December 13, 2022
Assignee:
Somerset Therapeutics, LLC
Inventors:
Mandar V. Shah, Ilango Subramanian, Veerappan Subramanian, Aman Trehan, Ojas Prakashbhai Doshi
Abstract: The discovery of mutant or fusion kinases that drive oncogenesis, and the subsequent approval of specific inhibitors for these enzymes, has been instrumental in the management of some cancers. However, acquired resistance remains a significant problem in the clinic, limiting the long-term effectiveness of most of these drugs. Herein is demonstrated a strategy to overcome this resistance through drug-induced MEK cleavage (via direct procaspase-3 activation) combined with targeted kinase inhibition. This combination effect is shown to be general across diverse tumor histologies (melanoma, lung cancer, and leukemia) and driver mutations (mutant BRAF or EGFR, fusion kinases EML4-ALK and BCR-ABL). Caspase-3-mediated degradation of MEK kinases results in sustained pathway inhibition and substantially delayed or eliminated resistance in cancer cells in a manner superior to combinations with MEK inhibitors.
Type:
Grant
Filed:
November 16, 2018
Date of Patent:
November 29, 2022
Assignee:
The Board of Trustees of the University of Illinois
Inventors:
Paul J. Hergenrother, Jessie Peh, Matthew Boudreau
Abstract: The disclosure provides a pediculicidal composition comprising a metal chelating agent; a carrier vehicle comprising water and an activating solvent system comprising an alcohol and a hydrocarbon. The carrier vehicle may be in the form of a solution, a cream, an ointment, a foam, a spray, an emulsion or a gel. The disclosure also provides method for use of a pediculicidal composition to treat human head lice and their eggs and methods for controlling head lice infestation.
Type:
Grant
Filed:
March 27, 2019
Date of Patent:
November 29, 2022
Inventors:
Ronald Harding, Lewis David Schulz, Vernon Morrison Bowles
Abstract: The present invention relates to benzimidazole derivatives of formula (I) as inhibitors of retinoid-related orphan receptor gamma (ROR?) protein, pharmaceutical compositions containing the compounds, preparation methods thereof, and the use of the compounds as therapeutic agents for the treatment of ROR?-mediated diseases or disorders.
Abstract: Disclosed is a method of treating cancer, e.g., refractory cancer, with tivozanib. The methods disclosed include, for example, administering tivozanib as a second or third-line therapy to subjects suffering from refractory advanced renal cell carcinoma where traditional therapies as well as more recent targeted and immune-oncology therapies have not adequately treated the subject.
Abstract: Disclosed herein are compositions and methods for the treatment of pulmonary hypertension, including pulmonary arterial hypertension. The methods include administering to a patient in need thereof an effective amount of Quetiapine or derivative thereof. The compositions include an effective amount of Quetiapine or derivative thereof, in some instances combined with one or more additional agents for the treatment of pulmonary hypertension.
Abstract: Provided herein are methods of administering pre-operative beverage compositions to be ingested by a patient prior to administration of anesthesia or sedation in preparation for a safe induction of anesthesia or sedation in a patient before surgery. The beverage has one or more carbohydrates, wherein the total Calories available from the carbohydrates is at least about 200 and wherein the one or more carbohydrates are the sole source of significant Calories in the beverage, an acid, in a quantity sufficient to result in a pH of at least about 3.7 to about 4.5 and to enhance the shelf life and flavor of the beverage, a central nervous system (CNS) stimulant that is also a cerebro-vasoconstrictor, a sweetener, and water. The beverage composition, when ingested at least about two hours prior to administration of anesthesia or sedation is effective to relieve one or more symptoms associated with prolonged fasting.
Abstract: The present invention relates to novel dihydropyridine derivatives of formula (I): as modulators of nuclear receptors selected from androgen receptor and glucocorticoid receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by modulation of androgen receptor and/or glucocorticoid receptor, selected from cancer, metastasizing cancers, benign prostate hyperplasia, polycystic ovary syndrome (PCOS), hair loss, hirsutism, acne, hypogonadism, muscle wasting diseases, cachexia, Cushing's syndrome, anti-psychotic drug induced weight gain, obesity, post-traumatic stress disorder and alcoholism.
Abstract: Provided are salts of (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine and various of crystal forms thereof, and compositions, medicaments, pharmaceutically acceptable formulations thereof, and methods of making same. In addition, provided are compounds comprising specific particle size distributions of crystalline (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine HCl and methods of making and modulating the particle size distributions.
Type:
Grant
Filed:
August 28, 2020
Date of Patent:
September 13, 2022
Assignee:
Sunovion Pharmaceuticals Inc.
Inventors:
Andrea Bauer, Nandkumar Nivritti Bhogle, Xiaoxia Chen, Shahla Jamzad, Robert Joseph Prytko, Kostas Saranteas, Michael Joseph Sizensky, Harold Scott Wilkinson, Haitao Zhang
Abstract: The present invention includes methods of treating or preventing HER-driven drug-resistant cancers. In certain embodiments, the cancer comprises lung cancer.
Type:
Grant
Filed:
September 7, 2018
Date of Patent:
August 30, 2022
Assignee:
The Regents of the University of Colorado
Abstract: Provided are a pyrroloquinoline quinone glycine betaine salt and a crystalline form thereof. The pyrroloquinoline quinone glycine betaine salt has the advantages of high solubility, good stability, a simple preparation process and low solvent residue.
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating an angiogenesis-related ocular disease comprising an inhibitor of MCT expression or MCT activity as an active ingredient, and it can effectively prevent or treat an angiogenesis-related ocular disease without affecting the normal function of VEGF required for maintaining homeostasis of choriocapillary and visual cells, by specifically inhibiting only VEGF secreted by macrophages, different from conventional treatment.
Type:
Grant
Filed:
July 1, 2020
Date of Patent:
August 9, 2022
Assignees:
SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Inventors:
Seung Hyeok Seok, Juha Song, Ki Hwang Lee
Abstract: The present invention relates to an ophthalmic composition comprising from 0.005% to 0.02% bimatoprost by weight and one or more pharmaceutically acceptable excipient, wherein said composition is free of benzalkonium chloride. The invention also relates to bimatoprost ophthalmic compositions comprising one or more penetration enhancers other than benzalkonium chloride. Further, the invention also provides a process of preparing such compositions and their use for lowering intraocular pressure and treating glaucoma.
Type:
Grant
Filed:
December 8, 2020
Date of Patent:
August 2, 2022
Assignee:
Somerset Therapeutics, LLC.
Inventors:
Mandar V Shah, Veerappan Subramanian, Ilango Subramanian, Aman Trehan
Abstract: The present disclosure provides for treating lysosomal storage disorders (LSDs) comprising administering acetyl-leucine or a pharmaceutically acceptable salt thereof.
Abstract: The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
Abstract: A method of treating cardiac hypertrophy and/or heart failure in a subject includes administering to the subject a therapeutically effective amount of a REV-ERB? agonist.
Type:
Grant
Filed:
February 9, 2018
Date of Patent:
July 19, 2022
Assignee:
CASE WESTERN RESERVE UNIVERSITY
Inventors:
Lilei Zhang, Mukesh K. Jain, Thomas Burris